Point72 (ATRA) holds 6.2% of Atara Biotherapeutics as of May 7, 2026
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Atara Biotherapeutics received a Schedule 13G reporting that Point72-affiliated entities beneficially own 526,682 shares of Common Stock, representing 6.2% of the class as of May 7, 2026. The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over these shares through Point72 Associates under a joint filing agreement. The reporting persons own no shares directly and the disclosure notes Point72 Associates has the right to receive dividends or sale proceeds for the reported position.
Positive
- None.
Negative
- None.
Key Figures
Shares beneficially owned: 526,682 shares
Percent of class: 6.2%
Reporting date: May 7, 2026
3 metrics
Shares beneficially owned
526,682 shares
as of May 7, 2026
Percent of class
6.2%
percent of common stock as reported in Item 4
Reporting date
May 7, 2026
ownership and voting/dispositive powers stated as of this date
Key Terms
Schedule 13G, beneficially owned, shared dispositive power, Joint Filing Agreement
4 terms
Schedule 13G regulatory
"This statement is filed by: (i) Point72 Asset Management... (Schedule 13G)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially owned financial
"Amount beneficially owned: The information required by Item 4(a) is set forth..."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Joint Filing Agreement legal
"have entered into a Joint Filing Agreement, a copy of which is filed with this as Exhibit 99.1"
FAQ
What stake does Point72 report in Atara Biotherapeutics (ATRA)?
Point72 reports beneficial ownership of 526,682 shares, or 6.2% of Atara's common stock. That figure is reported as of May 7, 2026 and appears in Row 9 of the cover page and Item 4 of the filing.
Which Point72 entities filed the Schedule 13G for ATRA?
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen filed jointly. The filing cites a Joint Filing Agreement and notes Cubist Systematic Strategies, LLC acts as a relying sub-adviser for a portion of the shares.